Abstract
Increased activity of MYC protein-family members is a common feature in many cancers. Using neuroblastoma as a tumor model, we established a microRNA (miRNA) signature for activated MYCN/c-MYC signaling in two independent primary neuroblastoma tumor cohorts and provide evidence that c-MYC and MYCN have overlapping functions. On the basis of an integrated approach including miRNA and messenger RNA (mRNA) gene expression data we show that miRNA activation contributes to widespread mRNA repression, both in c-MYC- and MYCN-activated tumors. c-MYC/MYCN-induced miRNA activation was shown to be dependent on c-MYC/MYCN promoter binding as evidenced by chromatin immunoprecipitation. Finally, we show that pathways, repressed through c-MYC/MYCN miRNA activation, are highly correlated to tumor aggressiveness and are conserved across different tumor entities suggesting that c-MYC/MYCN activate a core set of miRNAs for cooperative repression of common transcriptional programs related to disease aggressiveness. Our results uncover a widespread correlation between miRNA activation and c-MYC/MYCN-mediated coding gene expression modulation and further substantiate the overlapping functions of c-MYC and MYCN in the process of tumorigenesis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Adhikary S, Eilers M . (2005). Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol 6: 635–645.
Baek D, Villen J, Shin C, Camargo FD, Gygi SP, Bartel DP . (2008). The impact of microRNAs on protein output. Nature 455: 64–71.
Bartel DP . (2009). MicroRNAs: target recognition and regulatory functions. Cell 136: 215–233.
Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D et al. (2006). Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439: 353–357.
Cappellen D, Schlange T, Bauer M, Maurer F, Hynes NE . (2007). Novel c-MYC target genes mediate differential effects on cell proliferation and migration. EMBO Rep 8: 70–76.
Chang CC, Liu YC, Cleveland RP, Perkins SL . (2000). Expression of c-Myc and p53 correlates with clinical outcome in diffuse large B-cell lymphomas. Am J Clin Pathol 113: 512–518.
Chang TC, Yu D, Lee YS, Wentzel EA, Arking DE, West KM et al. (2008). Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet 40: 43–50.
Chen Y, Stallings RL . (2007). Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis. Cancer Res 67: 976–983.
Dews M, Homayouni A, Yu D, Murphy D, Sevignani C, Wentzel E et al. (2006). Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet 38: 1060–1065.
Fontana L, Fiori ME, Albini S, Cifaldi L, Giovinazzi S, Forloni M et al. (2008). Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM. PLoS One 3: e2236.
Fredlund E, Ringner M, Maris JM, Pahlman S . (2008). High Myc pathway activity and low stage of neuronal differentiation associate with poor outcome in neuroblastoma. Proc Natl Acad Sci USA 105: 14094–14099.
Gartel AL . (2006). A new mode of transcriptional repression by c-myc: methylation. Oncogene 25: 1989–1990.
Jiang M, Zhu K, Grenet J, Lahti JM . (2008). Retinoic acid induces caspase-8 transcription via phospho-CREB and increases apoptotic responses to death stimuli in neuroblastoma cells. Biochim Biophys Acta 1783: 1055–1067.
Kleine-Kohlbrecher D, Adhikary S, Eilers M . (2006). Mechanisms of transcriptional repression by Myc. Curr Top Microbiol Immunol 302: 51–62.
Kramer MH, Hermans J, Wijburg E, Philippo K, Geelen E, van Krieken JH et al. (1998). Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood 92: 3152–3162.
Landais S, Landry S, Legault P, Rassart E . (2007). Oncogenic potential of the miR-106-363 cluster and its implication in human T-cell leukemia. Cancer Res 67: 5699–5707.
Lee Y, Samaco RC, Gatchel JR, Thaller C, Orr HT, Zoghbi HY . (2008). miR-19, miR-101 and miR-130 co-regulate ATXN1 levels to potentially modulate SCA1 pathogenesis. Nat Neurosci 11: 1137–1139.
Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H et al. (2008). Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 359: 2313–2323.
Liu Y, Ringner M . (2007). Revealing signaling pathway deregulation by using gene expression signatures and regulatory motif analysis. Genome Biol 8: R77.
Malynn BA, de Alboran IM, O'Hagan RC, Bronson R, Davidson L, DePinho RA et al. (2000). N-myc can functionally replace c-myc in murine development, cellular growth, and differentiation. Genes Dev 14: 1390–1399.
Mestdagh P, Feys T, Bernard N, Guenther S, Chen C, Speleman F et al. (2008). High-throughput stem-loop RT-qPCR miRNA expression profiling using minute amounts of input RNA. Nucleic Acids Res 36: e143.
Mestdagh P, Van Vlierberghe P, De Weer A, Muth D, Westermann F, Speleman F et al. (2009). A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol 10: R64.
Northcott PA, Fernandez LA, Hagan JP, Ellison DW, Grajkowska W, Gillespie Y et al. (2009). The miR-17/92 polycistron is up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural precursors. Cancer Res 69: 3249–3255.
O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT . (2005). c-Myc-regulated microRNAs modulate E2F1 expression. Nature 435: 839–843.
Oberthuer A, Berthold F, Warnat P, Hero B, Kahlert Y, Spitz R et al. (2006). Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. J Clin Oncol 24: 5070–5078.
Park DS, Razani B, Lasorella A, Schreiber-Agus N, Pestell RG, Iavarone A et al. (2001). Evidence that Myc isoforms transcriptionally repress caveolin-1 gene expression via an INR-dependent mechanism. Biochemistry 40: 3354–3362.
Peterson S, Bogenmann E . (2004). The RET and TRKA pathways collaborate to regulate neuroblastoma differentiation. Oncogene 23: 213–225.
Saito-Ohara F, Imoto I, Inoue J, Hosoi H, Nakagawara A, Sugimoto T et al. (2003). PPM1D is a potential target for 17q gain in neuroblastoma. Cancer Res 63: 1876–1883.
Sampson VB, Rong NH, Han J, Yang Q, Aris V, Soteropoulos P et al. (2007). MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. Cancer Res 67: 9762–9770.
Sander S, Bullinger L, Klapproth K, Fiedler K, Kestler HA, Barth TF et al. (2008). MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. Blood 112: 4202–4212.
Schulte JH, Horn S, Otto T, Samans B, Heukamp LC, Eilers UC et al. (2008). MYCN regulates oncogenic microRNAs in neuroblastoma. Int J Cancer 122: 699–704.
Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY et al. (1985). Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 313: 1111–1116.
Selbach M, Schwanhausser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N . (2008). Widespread changes in protein synthesis induced by microRNAs. Nature 455: 58–63.
Stupack DG, Teitz T, Potter MD, Mikolon D, Houghton PJ, Kidd VJ et al. (2006). Potentiation of neuroblastoma metastasis by loss of caspase-8. Nature 439: 95–99.
Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al. (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102: 15545–15550.
Sun Y, Wu J, Wu SH, Thakur A, Bollig A, Huang Y et al. (2008). Expression profile of microRNAs in c-Myc induced mouse mammary tumors. Breast Cancer Res Treat 118: 185–196.
Tan LP, Seinen E, Duns G, de Jong D, Sibon OC, Poppema S et al. (2009). A high throughput experimental approach to identify miRNA targets in human cells. Nucleic Acids Res 37: e137.
Van Roy N, Laureys G, Cheng NC, Willem P, Opdenakker G, Versteeg R et al. (1994). 1;17 translocations and other chromosome 17 rearrangements in human primary neuroblastoma tumors and cell lines. Genes Chromosomes Cancer 10: 103–114.
Van Roy N, Vandesompele J, Menten B, Nilsson H, De Smet E, Rocchi M et al. (2006). Translocation-excision-deletion-amplification mechanism leading to nonsyntenic coamplification of MYC and ATBF1. Genes Chromosomes Cancer 45: 107–117.
Vandesompele J, Edsjo A, De Preter K, Axelson H, Speleman F, Pahlman S . (2003). ID2 expression in neuroblastoma does not correlate to MYCN levels and lacks prognostic value. Oncogene 22: 456–460.
Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F et al. (2006). A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103: 2257–2261.
Wang Q, Diskin S, Rappaport E, Attiyeh E, Mosse Y, Shue D et al. (2006). Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. Cancer Res 66: 6050–6062.
Watters JW, Roberts CJ . (2006). Developing gene expression signatures of pathway deregulation in tumors. Mol Cancer Ther 5: 2444–2449.
Westermann F, Muth D, Benner A, Bauer T, Henrich KO, Oberthuer A et al. (2008). Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas. Genome Biol 9: R150.
Zeller KI, Jegga AG, Aronow BJ, O'Donnell KA, Dang CV . (2003). An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets. Genome Biol 4: R69.
Acknowledgements
We acknowledge Q Wang and J Maris for providing the neuroblastoma microarray data set. This research was funded by the Gent University Research Fund (BOF 01D31406 to PM, BOF 01F07207 to FP, BOF 01Z09407 to J Vandesompele), the Fondation pour la recherche Nuovo-Soldati (J Vermeulen), RD06/0020/0102 from RTICC/ISCIII to RN, the Fund for Scientific Research (grant number: G.0198.08 and 31511809), the Belgian Kid's Fund and the Stichting tegen Kanker. KDP is a post-doctoral researcher with the Fund for Scientific Research-Flanders. We acknowledge the support of the European Community under the FP6 (project: STREP: EET-pipeline, number: 037260).
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc)
Supplementary information
Rights and permissions
About this article
Cite this article
Mestdagh, P., Fredlund, E., Pattyn, F. et al. MYCN/c-MYC-induced microRNAs repress coding gene networks associated with poor outcome in MYCN/c-MYC-activated tumors. Oncogene 29, 1394–1404 (2010). https://doi.org/10.1038/onc.2009.429
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2009.429
Keywords
This article is cited by
-
Role of non-coding RNAs in neuroblastoma
Cancer Gene Therapy (2023)
-
microRNA dynamic expression regulates invariant NKT cells
Cellular and Molecular Life Sciences (2021)
-
MicroRNA dysregulation interplay with childhood abdominal tumors
Cancer and Metastasis Reviews (2019)
-
ALK positively regulates MYCN activity through repression of HBP1 expression
Oncogene (2019)
-
Mimicking the tumour microenvironment of chronic lymphocytic leukaemia in vitro critically depends on the type of B-cell receptor stimulation
British Journal of Cancer (2016)